PT2928870T - Ligandos de recetores de neurotensina - Google Patents

Ligandos de recetores de neurotensina

Info

Publication number
PT2928870T
PT2928870T PT138148275T PT13814827T PT2928870T PT 2928870 T PT2928870 T PT 2928870T PT 138148275 T PT138148275 T PT 138148275T PT 13814827 T PT13814827 T PT 13814827T PT 2928870 T PT2928870 T PT 2928870T
Authority
PT
Portugal
Prior art keywords
receptor ligands
neurotensin receptor
neurotensin
ligands
receptor
Prior art date
Application number
PT138148275T
Other languages
English (en)
Original Assignee
3B Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3B Pharmaceuticals Gmbh filed Critical 3B Pharmaceuticals Gmbh
Publication of PT2928870T publication Critical patent/PT2928870T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0474Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT138148275T 2012-12-07 2013-12-06 Ligandos de recetores de neurotensina PT2928870T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12008208.6A EP2740726A1 (en) 2012-12-07 2012-12-07 Neurotensin receptor ligands

Publications (1)

Publication Number Publication Date
PT2928870T true PT2928870T (pt) 2020-05-29

Family

ID=47355771

Family Applications (2)

Application Number Title Priority Date Filing Date
PT138148275T PT2928870T (pt) 2012-12-07 2013-12-06 Ligandos de recetores de neurotensina
PT201664224T PT3712131T (pt) 2012-12-07 2013-12-06 Ligandos do recetor da neurotensina

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT201664224T PT3712131T (pt) 2012-12-07 2013-12-06 Ligandos do recetor da neurotensina

Country Status (21)

Country Link
US (2) US10961199B2 (pt)
EP (3) EP2740726A1 (pt)
JP (2) JP6576828B2 (pt)
KR (1) KR102290803B1 (pt)
CN (2) CN104837819B9 (pt)
AU (1) AU2013354422B2 (pt)
BR (1) BR112015012530B1 (pt)
CA (1) CA2893605C (pt)
DK (2) DK2928870T3 (pt)
ES (2) ES2941629T3 (pt)
FI (1) FI3712131T3 (pt)
HK (1) HK1210148A1 (pt)
HU (2) HUE050388T2 (pt)
IL (1) IL239080B (pt)
MX (1) MX370354B (pt)
PL (2) PL3712131T3 (pt)
PT (2) PT2928870T (pt)
RU (1) RU2671970C2 (pt)
SG (2) SG10201704564QA (pt)
WO (1) WO2014086499A1 (pt)
ZA (1) ZA201503446B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2954934A1 (en) * 2014-06-11 2015-12-16 3B Pharmaceuticals GmbH Conjugate comprising a neurotensin receptor ligand and use thereof
EP2954933A1 (en) * 2014-06-10 2015-12-16 3B Pharmaceuticals GmbH Conjugate comprising a neurotensin receptor ligand
EP3154638A1 (en) 2014-06-10 2017-04-19 3B Pharmaceuticals GmbH Conjugate comprising a neurotensin receptor ligand and use thereof
BR112018010535A2 (pt) 2015-11-24 2018-11-13 Transfert Plus Sec compostos peptídicos e conjugados peptídicos para o tratamento de câncer por quimioterapia com mediação por um receptor
EP3279197A1 (en) 2016-08-03 2018-02-07 Friedrich-Alexander-Universität Erlangen-Nürnberg Diagnosis, treatment and prevention of neurotensin receptor-related conditions
MA46952A (fr) 2016-12-01 2019-10-09 Regeneron Pharma Anticorps anti-pd-l1 radiomarqués pour imagerie immuno-pet
CN118557758A (zh) 2017-02-10 2024-08-30 瑞泽恩制药公司 用于免疫-pet成像的放射性标记的抗-lag3抗体
JP7304846B2 (ja) 2017-07-24 2023-07-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗cd8抗体およびその使用
US20220273831A1 (en) * 2019-07-08 2022-09-01 3B Pharmaceuticals Gmbh Compounds comprising a fibroblast activation protein ligand and use thereof
CN111875667B (zh) * 2020-07-16 2021-12-21 南方科技大学 有机金属螯合物及其制备方法与应用、探针
IL301868A (en) * 2020-10-22 2023-06-01 Nihon Mediphysics Co Ltd A method for preparing a radioactive zirconium complex
KR20240007257A (ko) * 2021-05-13 2024-01-16 더 제너럴 하스피탈 코포레이션 알데히드의 생체내 검출을 위한 분자 프로브
EP4355377A1 (en) * 2021-06-16 2024-04-24 Fusion Pharmaceuticals Inc. Combination comprising a neurotensin receptor binding compound, gemcitabine and nab-paclitaxel
WO2022261770A1 (en) * 2021-06-16 2022-12-22 Fusion Pharmaceuticals Inc. Combination comprising a neurotensin receptor binding compound and folfirinox
AU2023211720A1 (en) * 2022-01-28 2024-08-15 Fusion Pharmaceuticals Inc. Ntsr1-targeted radiopharmaceuticals and checkpoint inhibitor combination therapy
WO2023158802A1 (en) * 2022-02-18 2023-08-24 Full-Life Technologies U.S. Inc. Compounds and radioligands for targeting neurotensin receptor and uses thereof
WO2023215778A1 (en) * 2022-05-03 2023-11-09 The University Of North Carolina At Chapel Hill Development of ntsr targeted agents for imaging and therapy applications
US12091454B2 (en) 2022-12-28 2024-09-17 Development Center For Biotechnology Humanized anti-human neurotensin receptor 1 antibodies and their uses

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4110321A (en) 1976-07-12 1978-08-29 Folkers Karl Synthetic tridecapeptide [Gln4 ]-neurotensin having hormonal activity
US4425269A (en) 1982-06-07 1984-01-10 Merck & Co., Inc. Metabolically protected analogs of neurotensin
US4439359A (en) 1982-07-02 1984-03-27 Merck & Co., Inc. Cyclic octapeptide analogs of neurotensin
US4885363A (en) 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
US5021556A (en) 1987-07-22 1991-06-04 Neorx Corporation Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides
US5075099A (en) 1988-05-31 1991-12-24 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
FR2665898B1 (fr) 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5367080A (en) 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
US5965107A (en) 1992-03-13 1999-10-12 Diatide, Inc. Technetium-99m labeled peptides for imaging
CA2086453A1 (en) 1992-12-30 1994-07-01 Mcgill University Marker for neurotensin receptor
US5407916A (en) 1993-02-16 1995-04-18 Warner-Lambert Company Neurotensin mimetics as central nervous system agents
FR2711140B1 (fr) * 1993-10-12 1996-01-05 Sanofi Sa 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant.
JPH11514329A (ja) 1994-02-18 1999-12-07 マリンクロット・メディカル・インコーポレイテッド 標識化ペプチド化合物
US6054557A (en) 1995-04-04 2000-04-25 Advanced Bioconcept (1994) Ltd. Fluorescent peptides
EP0820466A2 (en) 1995-04-04 1998-01-28 Advanced Bioconcept Inc. Fluorescent peptides
FR2732967B1 (fr) 1995-04-11 1997-07-04 Sanofi Sa 1-phenylpyrazole-3-carboxamides substitues, actifs sur la neurotensine, leur preparation, les compositions pharmaceutiques en contenant
AU6352296A (en) 1995-07-20 1997-02-18 Advanced Bioconcept, Inc. Cell sorting with fluorescent peptides
CA2279530C (en) 1997-02-03 2009-04-28 Mallinckrodt Inc. A method for the detection and localization of ductal exocrine pancreas tumours
US5886142A (en) 1997-05-20 1999-03-23 Thomas Jefferson University Radiolabeled thrombus imaging agents
WO1999052539A1 (en) 1998-04-10 1999-10-21 Mayo Foundation For Medical Education And Research Neo-tryptophan
CA2374270A1 (en) 1999-06-24 2000-12-28 Ananthachari Srinivasan Labeled neurotensin derivatives
EP2338525A3 (en) * 2003-07-09 2011-08-03 California Pacific Medical Center Remote detection of substance delivery to cells
US20060062729A1 (en) * 2004-09-09 2006-03-23 Carraway Robert E Enhanced ligand binding to neurotensin receptors
US20100111858A1 (en) * 2007-01-19 2010-05-06 Howard Carol P Diangostic and Therapeutic Cyclooxygenase-2 Binding Ligands
EP2100900A1 (en) 2008-03-07 2009-09-16 Universitätsspital Basel Bombesin analog peptide antagonist conjugates
EP2334642B1 (en) * 2008-09-16 2014-01-01 The Regents Of The University Of California Simplified one-pot synthesis of [18f]sfb for radiolabeling
CA2745524C (en) 2008-12-05 2020-06-09 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
EP2374003B1 (en) * 2009-01-07 2015-03-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment, the prognostic assessment and the detection of breast cancer
WO2011006985A1 (en) 2009-07-16 2011-01-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Neurotensin analogues for radioisotope targeting to neurotensin receptor-positive tumors
WO2011156557A2 (en) * 2010-06-11 2011-12-15 Thomas James B Compounds active at the neurotensin receptor

Also Published As

Publication number Publication date
JP7042776B2 (ja) 2022-03-28
AU2013354422B2 (en) 2018-03-15
SG10201704564QA (en) 2017-07-28
WO2014086499A8 (en) 2014-12-31
IL239080A0 (en) 2015-07-30
EP2928870A1 (en) 2015-10-14
HUE050388T2 (hu) 2020-11-30
DK2928870T3 (da) 2020-07-13
CN109320502B (zh) 2022-06-07
MX2015007193A (es) 2016-03-17
BR112015012530B1 (pt) 2022-07-19
PL3712131T3 (pl) 2023-05-02
HUE061839T2 (hu) 2023-08-28
US20210087149A1 (en) 2021-03-25
KR20150092300A (ko) 2015-08-12
JP2016501238A (ja) 2016-01-18
CN104837819A (zh) 2015-08-12
ES2795923T3 (es) 2020-11-25
CN104837819B (zh) 2018-12-07
RU2015127086A (ru) 2017-01-11
ES2941629T3 (es) 2023-05-24
EP2740726A1 (en) 2014-06-11
PL2928870T3 (pl) 2020-09-21
EP3712131A1 (en) 2020-09-23
FI3712131T3 (fi) 2023-03-28
KR102290803B1 (ko) 2021-08-18
RU2671970C2 (ru) 2018-11-08
EP2928870B1 (en) 2020-04-08
JP2019218375A (ja) 2019-12-26
US20150299133A1 (en) 2015-10-22
SG11201503880YA (en) 2015-06-29
IL239080B (en) 2019-06-30
DK3712131T3 (da) 2023-03-20
US10961199B2 (en) 2021-03-30
CN104837819B9 (zh) 2019-07-09
JP6576828B2 (ja) 2019-09-18
BR112015012530A2 (pt) 2017-09-12
HK1210148A1 (en) 2016-04-15
PT3712131T (pt) 2023-04-04
ZA201503446B (en) 2016-01-27
EP3712131B1 (en) 2023-02-01
CA2893605A1 (en) 2014-06-12
MX370354B (es) 2019-12-10
CN109320502A (zh) 2019-02-12
CA2893605C (en) 2021-08-10
AU2013354422A1 (en) 2015-05-28
WO2014086499A1 (en) 2014-06-12

Similar Documents

Publication Publication Date Title
IL254716A0 (en) Zinc-lysine conjugate
HK1210148A1 (en) Neurotensin receptor ligands
HK1211039A1 (en) Engineering -cell receptors
DK3327112T3 (en) Agse-deficient stamme
GB201213700D0 (en) Receptor antagnists II
EP2754580A4 (en) DUMP TRUCK
DK2830816T3 (en) Hidtil ukendt coatingkoncept
EP2876220A4 (en) DREDGING
EP2935220A4 (en) PERI-carbinol
EP2920142A4 (en) MÉTHANOFULLERRÈNES
EP2812698A4 (en) TIME RESOLVED FREIGHT AND DOUBLE ACCEPTOR
EP2920157A4 (en) DI MACRO CYCLEN
EP2873363A4 (en) DIOPSIMETER
GB201223053D0 (en) Receptor
GB2500883B (en) Improved saw-horse
EP2834250A4 (de) Lithiumsilikate
ZA201305187B (en) Improved brattice
GB201215542D0 (en) Securing means
GB201220595D0 (en) Keysafe application
AU345893S (en) Treehouse
GB201212986D0 (en) Fairscrabble
GB201202303D0 (en) Myhealthbadge
GB201202208D0 (en) Easomark
GB201201767D0 (en) Pop-tops
GB201201668D0 (en) LOCnlatch